Primum non nocere. Quomo sapere?. Firstly, do no harm. How can we know this? Drug-eluting stents versus surgery.
暂无分享,去创建一个
[1] F. Zijlstra,et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study , 2008, The Lancet.
[2] R. Higgins,et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. , 2008, The New England journal of medicine.
[3] Marco Valgimigli,et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. , 2007, European heart journal.
[4] Simon Wandel,et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.
[5] Á. Atallah,et al. Drug-eluting stent in diabetes. , 2007, Sao Paulo medical journal = Revista paulista de medicina.
[6] Á. Atallah,et al. Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent? , 2007, Sao Paulo medical journal = Revista paulista de medicina.
[7] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[8] Johan Lindbäck,et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.
[9] Marco Valgimigli,et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[10] P. Serruys,et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.
[11] A James O'Malley,et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. , 2005, The American journal of cardiology.